GlassScriptPhysician profile
Christopher J Phillips
NPI 1487755195
$6,964.64
in general payments reported to CMS, 2019-2025
28 companies · $835 in 2025
The $835 reported for 2025 was more than what 94% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,061 · 2020: $520 · 2021: $1,273 · 2022: $1,149 · 2023: $1,203 · 2024: $923 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,961.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,240.65 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $741.43 | 2019-2025 | |
| Abbvie INC. | $702.94 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $611.93 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $602.60 | 2019-2024 | Lokelma, Farxiga |
| Merck Sharp & Dohme LLC | $521.71 | 2019-2025 | Zerbaxa, Dificid, Verquvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $343.52 | 2020-2025 | Xifaxan |
| Allergan, INC. | $305.14 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $294.45 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $263.28 | 2019-2024 | Camzyos, Eliquis |
| Alexion Pharmaceuticals, INC. | $193.43 | 2019-2025 | Ultomiris |
| Abbott Laboratories | $136.29 | 2024-2025 | I-Stat, Mitraclip |
| Paratek Pharmaceuticals, INC. | $127.36 | 2022-2023 | Nuzyra |
| Jazz Pharmaceuticals INC. | $111.83 | 2022 | |
| Gilead Sciences, INC. | $105.55 | 2021-2023 | Veklury |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $99.19 | 2019 | |
| Novo Nordisk INC | $95.44 | 2019-2024 | Rybelsus, Ozempic |
| Boston Scientific Corporation | $92.91 | 2019-2024 | Watchman Flx |
| Sunovion Pharmaceuticals INC. | $92.65 | 2019 | |
| Sk Life Science, INC. | $67.05 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.19 | 2025 | Lifevest |
| Cmp Pharma, INC. | $46.19 | 2021 | |
| Shire North American Group INC | $27.52 | 2019 | |
| Amgen INC. | $26.81 | 2022 | |
| Smith+Nephew, INC. | $19.44 | 2025 | Collagenase Santyl |
| Melinta Therapeutics, LLC | $17.55 | 2021 | |
| Electromed, INC. | $15.38 | 2023 | Smartvest |
| Philips North America LLC | $14.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.